Salvage radiofrequency ablation followed by external beam radiotherapy for inoperable recurrent differentiated thyroid cancer

References

• Bureau of Health Promotion, Department of Health, Taiwan. Cancer Registry Annual Report. Published January 13, 2022. https://www.hpa.gov.tw/Pages/List.aspx?nodeid=269 (accessed May 12, 2022).
   Google Scholar
• Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1–10. doi: 10.1210/jcem.86.4.7407.
   Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428. doi: 10.1016/0002-9343(94)90321-2.
   PubMed Web of Science ®Google Scholar
• Choi Y, Jung SL, Bae JS, et al. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: a single-center propensity score matching study. Int J Hyperthermia. 2019;36(1):359–367.
   PubMed Web of Science ®Google Scholar
• Sippel RS, Chen H. Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer. Thyroid. 2009;19(12):1373–1380. doi: 10.1089/thy.2009.1606.
   PubMed Web of Science ®Google Scholar
• Chung SR, Baek JH, Choi YJ, et al. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. Eur Radiol. 2019;29(9):4897–4903. doi: 10.1007/s00330-019-06063-5.
   PubMed Web of Science ®Google Scholar
• Kim JH, Yoo WS, Park YJ, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. Radiology. 2015;276(3):909–918. doi: 10.1148/radiol.15140079.
   PubMed Web of Science ®Google Scholar
• Suh CH, Baek JH, Choi YJ, et al. Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: a systematic review and Meta-Analysis. Thyroid. 2016;26(3):420–428. doi: 10.1089/thy.2015.0545.
   PubMed Web of Science ®Google Scholar
• Lin WC, Chen WC, Wang PW, et al. 2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation. Ultrasonography. 2023;42(3):357–375. doi: 10.14366/usg.22126.
   PubMed Web of Science ®Google Scholar
• Mauri G, Hegedüs L, Cazzato RL, et al. Minimally invasive treatment procedures have come of age for thyroid malignancy: the 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Cardiovasc Intervent Radiol. 2021;44(9):1481–1484. doi: 10.1007/s00270-021-02870-w.
   PubMed Web of Science ®Google Scholar
• Lee M, Baek JH, Suh CH, et al. Clinical practice guidelines for radiofrequency ablation of benign thyroid nodules: a systematic review. Ultrasonography. 2021;40(2):256–264. doi: 10.14366/usg.20015.
   PubMed Web of Science ®Google Scholar
• Kim J-H, Baek JH, Lim HK, et al. 2017 Thyroid radiofrequency ablation guideline: korean society of thyroid radiology. Korean J Radiol. 2018;19(4):632–655. doi: 10.3348/kjr.2018.19.4.632.
   PubMed Web of Science ®Google Scholar
• Shin JE, Baek JH, Lee JH. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol. 2013;25(1):14–19. doi: 10.1097/CCO.0b013e32835a583d.
   PubMed Web of Science ®Google Scholar
• Chung SR, Baek JH, Choi YJ, et al. Efficacy of radiofrequency ablation for recurrent thyroid cancer invading the airways. Eur Radiol. 2021;31(4):2153–2160. doi: 10.1007/s00330-020-07283-w.
   PubMed Web of Science ®Google Scholar
• Terezakis SA, Lee KS, Ghossein RA, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: memorial sloan-kettering cancer center experience. Int J Radiat Oncol Biol Phys. 2009;73(3):795–801.
   PubMed Web of Science ®Google Scholar
• Brierley JD, Tsang RW. External beam radiation therapy for thyroid cancer. Endocrinol Metab Clin North Am. 2008;37(2):497–509, xi. doi: 10.1016/j.ecl.2008.02.001.
   PubMed Web of Science ®Google Scholar
• Keum KC, Suh YG, Koom WS, et al. The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys. 2006;65(2):474–480.
   PubMed Web of Science ®Google Scholar
• Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74(4):1083–1091. doi: 10.1016/j.ijrobp.2008.09.023.
   PubMed Web of Science ®Google Scholar
• Shindo ML, Caruana SM, Kandil E, et al. Management of invasive well-differentiated thyroid cancer: an American head and neck society consensus statement. AHNS consensus statement. Head Neck. 2014;36(10):1379–1390. doi: 10.1002/hed.23619.
   PubMed Web of Science ®Google Scholar
• Lim HK, Baek JH, Lee JH, et al. Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer. Eur Radiol. 2015;25(1):163–170. doi: 10.1007/s00330-014-3405-5.
   PubMed Web of Science ®Google Scholar
• Jeong WK, Baek JH, Rhim H, et al. Radiofrequency ablation of ­benign thyroid nodules: safety and imaging follow-up in 236 ­patients. Eur Radiol. 2008;18(6):1244–1250. doi: 10.1007/s00330-008-0880-6.
   PubMed Web of Science ®Google Scholar
• Baek JH, Kim YS, Lee D, et al. Benign predominantly solid thyroid nodules: prospective study of efficacy of sonographically guided radiofrequency ablation versus control condition. AJR Am J Roentgenol. 2010;194(4):1137–1142. doi: 10.2214/AJR.09.3372.
   PubMed Web of Science ®Google Scholar
• Lin WC, Wang CK, Wang WH, et al. Multicenter study of benign thyroid nodules with radiofrequency ablation: results of 762 cases over 4 years in Taiwan. J Pers Med. 2022;12(1):63.
   Web of Science ®Google Scholar
• Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–1952. doi: 10.1056/NEJMoa032641.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk Squamous-Cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–1944. doi: 10.1056/NEJMoa032646.
   PubMed Web of Science ®Google Scholar
• Sacks D, McClenny TE, Cardella JF, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–S202. doi: 10.1097/01.rvi.0000094584.83406.3e.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed June 14, 2023.
   Google Scholar
• Strojan P, Hutcheson KA, Eisbruch A, et al. Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev. 2017;59:79–92.
   PubMed Web of Science ®Google Scholar
• Ortigara GB, Bonzanini LIL, Schulz RE, et al. Late radiation effects in survivors of head and neck cancer: state of the science. Crit Rev Oncol Hematol. 2021;162:103335. doi: 10.1016/j.critrevonc.2021.103335.
   PubMed Web of Science ®Google Scholar
• Tufano RP, Pace-Asciak P, Russell JO, et al. Update of radiofrequency ablation for treating benign and malignant thyroid nodules. The future is now. Front Endocrinol (Lausanne). 2021;12:698689. doi: 10.3389/fendo.2021.698689.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Head and Neck Cancers (version 2. 2024). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Published 2024. Accessed.
   Google Scholar
• Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. The Journal of Clinical Endocrinology & Metabolism. 1992;75(3):714–720.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Tian G, Kong D, et al. Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers. J Endocrinol Invest. 2016;39(8):909–916. doi: 10.1007/s40618-016-0450-8.
   PubMed Web of Science ®Google Scholar
• Baek JH, Kim YS, Sung JY, et al. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol. 2011;197(2):W331–336.
   PubMed Web of Science ®Google Scholar
• Heilo A, Sigstad E, Fagerlid KH, et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96(9):2750–2755. doi: 10.1210/jc.2010-2952.
   PubMed Web of Science ®Google Scholar
• Park KW, Shin JH, Han BK, et al. Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol. 2011;18(9):2564–2568. doi: 10.1245/s10434-011-1619-1.
   PubMed Web of Science ®Google Scholar
• Lee MK, Baek JH, Chung SR, et al. Radiofrequency ablation of recurrent thyroid cancers: anatomy-based management. Ultrasonography. 2022;41(3):434–443. doi: 10.14366/usg.21221.
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi: 10.1089/thy.2015.0020.
   PubMed Web of Science ®Google Scholar
• Groen AH, van Dijk D, Sluiter W, et al. Postoperative external beam radiotherapy for locoregional control in iodine refractory differentiated thyroid cancer. Eur Thyroid J. 2022;11(1):e210033. doi: 10.1530/ETJ-21-0033.
   PubMed Web of Science ®Google Scholar
• Romesser PB, Sherman EJ, Whiting K, et al. Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: a prospective phase 2 trial. Cancer. 2021;127(22):4161–4170. doi: 10.1002/cncr.33804.
   PubMed Web of Science ®Google Scholar
• Lee N, Xia P, Fischbein NJ, et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57(1):49–60. doi: 10.1016/s0360-3016(03)00405-x.
   PubMed Web of Science ®Google Scholar
• Bachelot A, Cailleux AF, Klain M, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12(8):707–711. doi: 10.1089/105072502760258686.
   PubMed Web of Science ®Google Scholar
• Kim TH, Chung KW, Lee YJ, et al. The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer. Radiat Oncol. 2010;5(1):69. doi: 10.1186/1748-717X-5-69.
   PubMedGoogle Scholar
• Urbano TG, Clark CH, Hansen VN, et al. Intensity modulated radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol. 2007;85(1):58–63.
   PubMed Web of Science ®Google Scholar
• Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol. 2001;61(3):223–231. doi: 10.1016/s0167-8140(01)00429-7.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi: 10.1056/NEJMoa1406470.
   PubMed Web of Science ®Google Scholar
• Brose MS, Worden FP, Newbold KL, et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 2017;35(23):2692–2699. doi: 10.1200/JCO.2016.71.6472.
   PubMed Web of Science ®Google Scholar
• Aashiq M, Silverman DA, Na’ara S, et al. Radioiodine-Refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies. Cancers (Basel). 2019;11(9):1382. doi: 10.3390/cancers11091382.
   PubMed Web of Science ®Google Scholar
• Haugen B, French J, Worden FP, et al. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol. 2020;38(15_suppl):6512–6512. doi: 10.1200/JCO.2020.38.15_suppl.6512.
   Web of Science ®Google Scholar